| Symbol | AQIA |
|---|---|
| Name | AQUIVA GROUP INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 20814 United States MD #3 Bethesda Metro Center Suite 700 |
| Telephone | +1 2025365191 |
| Fax | — |
| — | |
| Website | http://www.aquivamedical.com/ |
| Incorporation | US |
| Incorporated On | 2005 |
| Employees | — |
| Fiscal Year | 3/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Beckles & Co; |
| Audit Status | UNAUDITED |
| Reporting Status | Alternative Reporting Standard |
| CIK | 0001364139 |
| Description | BHPA, D/B/A Aquiva Medical Inc. is a biotechnology company focused on commercializing innovative materials science technologies to disrupt and enhance the future of transdermal drug delivery systems (TDDS). The companys wholly-owned subsidiary, Aquiva Medical, has exclusively licensed a novel HiPNATM (Hydrogel with Inter-Penetrating Network Anchor) technology, which is a unique and attractive platform technology for various applications to deliver active ingredients and pharmaceuticals via transdermal patches on the skin and surrounding tissues, including the ability to better control release dosage and speed for a broader range of molecules, with more precision than existing, legacy TDDS technologies. Aquivas current focus is on disrupting the $10.5B transdermal patch market for therapeutics. Additional info from OTC: |
No news found.